Alpha-synuclein Aggregation in Parkinson's Disease - Is it Relevant and How can we Model it?

Presented at: Neuroscience 2021
C.E. Credits: P.A.C.E. CE Florida CE
Speaker

Abstract

Parkinson’s disease (PD) is the second most common neurodegenerative disorder with multiple motor and non-motor symptoms. PD is characterized by the presence on proteinaceous neuronal inclusions (Lewy bodies) which are increasingly observed in multiple brain regions during disease progression. One of the main components in Lewy bodies is misfolded α-synuclein. Studies in animal models and PD patients strongly support α-synuclein contribution in PD progression. Inoculation with extracts from PD patients’ brains induces the development and spread of α-synuclein pathology in rodents, non-human primates, and iPSC-derived human neurons. Thus, α-synuclein has emerged as a promising target for developing disease-modifying therapies, aiming at interfering with initial aggregation by small molecules; enhancing degradation of intracellular α-synuclein by stimulating lysosomal activity; lowering cellular α-synuclein levels by anti-sense oligonucleotides and cell-penetrant nanobodies; inhibiting uptake and targeting transmission of extracellular α-synuclein with active and passive immunization. Pre-formed fibrils (PFFs) able to seed aggregation of endogenous α-synuclein in cultured cells and in vivo have become an essential experimental tool to model and study pathological protein aggregation. PFF model allows investigating the uptake of pathogenic fibrils, their internalization, transport, processing and recruitment of endogenous α-synuclein, formation and maturation of Lewy body-like inclusions and effects of these processes on cell function and survival. With α-synuclein PFFs we can study the mechanism of pathology transmission, motor and behavioral outcomes of accumulation of α-synuclein deposits in different brain structures. While the processes of α-synuclein misfolding and pathology progression are still not fully clear, α-synuclein PFFs have been and will be very instrumental for solving these problems.

Learning Objectives:

1. Define main problems in developing disease-modifying therapies for Parkinson’s disease

2. Identify current therapeutic strategies for Parkinson’s disease treatment

3. Analyze benefits and limitations of modelling alpha-synuclein pathology with pre-formed fibrils


Show Resources
You May Also Like
MAY 11, 2021 10:00 AM PDT
C.E. CREDITS
MAY 11, 2021 10:00 AM PDT
Date: May 11, 2021 Time: 10:00zm PDT Your samples are some of the most valuable assets in the laboratory. After spending countless hours on extraction and preparation, your conclusions could...
SEP 14, 2021 7:00 AM PDT
C.E. CREDITS
SEP 14, 2021 7:00 AM PDT
Date: September 14, 2021 Time: 7am PDT, 10am EDT, 4pm CEST A conventional thermal cycler has long been a commodity product in the lab and end-point PCR techniques can be completed almost wit...
JUN 09, 2021 7:00 AM PDT
C.E. CREDITS
JUN 09, 2021 7:00 AM PDT
Date: June 9, 2021 Time: 09 June 2021, 7am PDT, 10am EDT, 4pm CEST cells with dramatic implications on the validity of past cell culture related research. The fact that at least 509 cell lin...
SEP 17, 2021 12:00 PM CST
C.E. CREDITS
SEP 17, 2021 12:00 PM CST
Date: September 16, 2021 Time: 9:00pm (PDT), 12:00am (EDT) 3D cellular models like organoids and spheroids offer an opportunity to better understand complex biology in a physiologically rele...
APR 21, 2021 5:00 PM CEST
APR 21, 2021 5:00 PM CEST
Date: April 21, 2021 Time: 8:00am (PDT), 11:00am (EDT), 5:00pm (CEST) Spatial Answers Trilogy - Spatial Answers in Immunology Immunology Researchers share their Spatial Discoveries in SARS-C...
APR 01, 2021 8:00 AM PDT
C.E. CREDITS
APR 01, 2021 8:00 AM PDT
Date: April 01, 2021 Time: 8:00am (PST), 11:00am (EST) Generating therapeutic antibodies is far more challenging than obtaining antibodies that merely recognize their targets. Engineering po...
Loading Comments...
Show Resources